AlphAIalphai — Financial news for AI agents
fool.comAUG 203 min read$CLRB

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript

Cellectar Biosciences (CLRB) reported Q2 2026 earnings with $34M in cash, up from $13.2M at year-end 2025. The company raised $31.7M net from a May 2026 financing, with potential for $140M total. R&D expenses increased to $4.6M, while net loss was $6.9M. Clinical data showed promising results for iopofosine I 131 in Waldenstrom's macroglobulinemia, with a 79.2% response rate in post-BTKi patients. The company plans to initiate a Phase 3 trial by late 2026 or early 2027, targeting mid-2027 NDA su

Original reporting
fool.com
Published Aug 20, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$CLRBNeutralMed
01

Why it matters

The disclosed financing and trial milestones reduce near‑term liquidity risk but the company remains early‑stage with high execution risk.

02

Market read

Provides fresh data for traders tracking small‑cap biotech financing and clinical trial catalysts.

03

What to watch

Supply‑chain risk for actinium isotopes and potential competition in Waldenstrom's macroglobulinemia could constrain upside.

Relevance 6/10Novelty 7/10Timing: post‑earnings Q2 2026 release

Background

Cellectar Biosciences provided its Q2 2026 earnings call, highlighting cash balance, financing, net loss, and progress on its radiopharmaceutical pipeline.

Company-level read

Ticker impact

$CLRBNeutralMedium confidence
Context

Q2 2026 earnings call disclosed $34M cash, $31.7M net financing, $6.9M net loss and detailed clinical trial updates for iopofosine and CLR 125.

Expected impact

Potential modest upside if trial data remains positive; downside risk if FDA delays.

Evidence & confidence

New capital and trial milestones reduce near‑term funding risk, but loss magnitude and early‑stage data keep volatility high.

Market effects

Sector

Biotech sector may see slight lift as financing and trial progress signal continued capital availability for radiopharmaceuticals.

Regional

U.S. biotech investors could re‑allocate to early‑stage oncology pipelines.

Global

Limited; primarily affects U.S. small‑cap biotech investors.

Counterpoint

What could challenge this read

Despite fresh cash, the company remains loss‑making with unproven products; a short position may be justified.

Key entities

  • Company
    Cellectar Biosciences

    U.S. biotech developing radiopharmaceuticals for oncology.

  • Executive
    James Caruso

    President and CEO of Cellectar.

Read at source← All news

Related articles

AUG 22
$CLRBMedAI 8/10

Cellectar Biosciences Earnings Call Highlights Clinical Momentum - TipRanks.com

Cellectar Biosciences (CLRB) reported Q2 earnings, highlighting strong clinical data for iopofosine and a clear regulatory path. The CLOVER-WaM study showed high response rates in Waldenstrom’s macroglobulinemia. The company plans a Phase III trial and accelerated approval submission in 2027. Financing of up to $140M was secured, improving cash position to $34M. R&D expenses increased, widening net loss to $6.9M. Management acknowledged dilution risks and operational challenges.

tipranks.com3 min
AUG 17
$CLRBMed

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

yahoo.com7 min
AUG 13
$CLRBMed

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

rttnews.com5 min
AUG 13
$CLRBMed

Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2026 results and corporate updates. It initiated site activation for a Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA planned for mid-2027 under FDA Accelerated Approval. ASCO data showed 79.2% MRR (n=24) post-BTKi. CLR 125 Phase 1b TNBC enrollment began. Cash was $34.0M at June 30, 2026.

finanznachrichten.de7 min
AUG 13
$CLRBMed

Cellectar Biosciences, Inc. (CLRB): Results of Operations and Financial Condition

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Appro

SEC EDGAR 8-K6 min
SEP 8
$EQIXMedAI 8/10

Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here

Equinix (EQIX) reported Q2 revenue of $2.63B, up 16% YoY, beating estimates. AFFO was $11.78/share, up 19% YoY. The company raised full-year guidance and unveiled a multi-year growth plan. EQIX stock has surged 34% over the past year and offers a 1.98% dividend yield. Analysts rate it a 'Strong Buy' with an average price target of $1,232.19.

yahoo.com3 min